Novo Nordisk is to cut 11 per cent of jobs and has reduced its profit guidance for this year, as the Danish maker of weight-loss drugs Ozempic and Wegovy struggles to fend off competition from US rival Eli Lilly.
诺和诺德(Novo Nordisk)将裁员11%，并下调今年的利润指引。这家生产减肥药诺和泰(Ozempic)和诺和盈(Wegovy)的丹麦公司正在努力抵御来自美国竞争对手礼来(Eli Lilly)的竞争。
您已阅读8%（315字），剩余92%（3461字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。